MA27117A1 - (imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmda - Google Patents
(imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmdaInfo
- Publication number
- MA27117A1 MA27117A1 MA27943A MA27943A MA27117A1 MA 27117 A1 MA27117 A1 MA 27117A1 MA 27943 A MA27943 A MA 27943A MA 27943 A MA27943 A MA 27943A MA 27117 A1 MA27117 A1 MA 27117A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- neurodegeneration
- compounds
- pyridazine
- imidazol
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- GFSWLEBKUPUQNQ-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)pyridazine Chemical compound C1=CN=CN1CC1=CC=CN=N1 GFSWLEBKUPUQNQ-UHFFFAOYSA-N 0.000 title 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
(IMIDAZOL-1-YL-MÉTHYL)-PYRIDAZINE EN TANT QU'ANTAGONISTE DU RÉCEPTEUR POUR LE NMDA La présente invention concerne des composés de formule (I) dans laquelle A est un groupe cyclique non substitué; et R est l'hydrogène ou un alkyle inférieur; et des sels pharmaceutiquement acceptables de ceux-ci. Il s'est avéré que les composés de formule IA et IB sont de bons antagonistes spécifiques du sous-type de récepteurs pour le NMDA NR-2B. Des indications thérapeutiques possibles pour ces composés comprennent des formes aigues de neurodégénérescence provoquées, par exemple, par l'apoplexie et des traumatismes cérébraux, et des formes chroniques de neurodégénérescence telles que la maladie d'Alzheimer, la maladie de Parkinson, la maladie de Huntington, la SLA (sclérose latérale amyotrophique) et la neurodégénérescence associée à des infections bactériennes ou virales et, en outre, la dépression et la douleur chronique et aigue.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02010217 | 2002-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27117A1 true MA27117A1 (fr) | 2004-12-20 |
Family
ID=29433072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27943A MA27117A1 (fr) | 2002-05-16 | 2004-11-12 | (imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmda |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7005432B2 (fr) |
| EP (1) | EP1506190B1 (fr) |
| JP (1) | JP4267569B2 (fr) |
| KR (1) | KR100632868B1 (fr) |
| CN (1) | CN1312151C (fr) |
| AR (1) | AR040010A1 (fr) |
| AT (1) | ATE329912T1 (fr) |
| AU (1) | AU2003242542B2 (fr) |
| BR (1) | BR0311177A (fr) |
| CA (1) | CA2485926C (fr) |
| CL (1) | CL2004001251A1 (fr) |
| CY (1) | CY1105159T1 (fr) |
| DE (1) | DE60306152T2 (fr) |
| DK (1) | DK1506190T3 (fr) |
| ES (1) | ES2265581T3 (fr) |
| HR (1) | HRP20041060B1 (fr) |
| IL (1) | IL164922A (fr) |
| MA (1) | MA27117A1 (fr) |
| ME (1) | MEP76708A (fr) |
| MX (1) | MXPA04011253A (fr) |
| NO (1) | NO329605B1 (fr) |
| NZ (1) | NZ536310A (fr) |
| PL (1) | PL211340B1 (fr) |
| PT (1) | PT1506190E (fr) |
| RS (1) | RS51200B (fr) |
| RU (1) | RU2317294C2 (fr) |
| SI (1) | SI1506190T1 (fr) |
| TN (1) | TNSN04224A1 (fr) |
| WO (1) | WO2003097637A1 (fr) |
| ZA (1) | ZA200408789B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| EP1888706B1 (fr) | 2005-05-03 | 2017-03-01 | Merck Patent GmbH | Dispositif electroluminescent organique, et derives d'acide boronique et d'acide borinique utilises pour produire ce dispositif electroluminescent organique |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法 |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| US20110053951A1 (en) * | 2008-03-27 | 2011-03-03 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| BRPI1008498B8 (pt) | 2009-02-05 | 2021-05-25 | Takeda Pharmaceuticals Co | compostos de piridazinona úteis como inibidores da fosfodiesterase 10a, composição farmacêutica, e, uso de um composto |
| EP2602255B1 (fr) * | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Composé à cycle hétérocyclique fusionné |
| WO2012019106A2 (fr) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Modulateurs positifs et négatifs des récepteurs nmda |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| EP3180329B1 (fr) * | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Derives de triazole comme des inhibiteurs de recepteur nr2b |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| BR112018016794B1 (pt) | 2016-02-18 | 2022-07-19 | Syngenta Participations Ag | Compostos derivados de pirazol ativos em termos pesticidas, composição pesticida, método para controle de pragas, método para a proteção de material de propagação vegetal do ataque por pragas e material de propagação vegetal |
| WO2017158147A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale |
| WO2017158151A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| EP3774732A4 (fr) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| EP3983413A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| TR199801774T2 (xx) * | 1996-03-08 | 1998-12-21 | F.Hoffmann-La Roche Ag | 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�. |
| CA2220649C (fr) | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | Derives de 4-hydroxy-piperidine |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| JP4219590B2 (ja) | 2000-04-20 | 2009-02-04 | エフ．ホフマン−ラ ロシュ アーゲー | ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用 |
| US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| AU2001296994A1 (en) | 2000-10-06 | 2002-04-15 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| CA2381630A1 (fr) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Methode de prevention de la dyskinesie |
| DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 CA CA002485926A patent/CA2485926C/fr not_active Expired - Fee Related
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active Expired - Fee Related
- 2003-05-16 EP EP03752750A patent/EP1506190B1/fr not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/fr not_active Ceased
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
-
2006
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04224A1 (fr) | (imidazol-1 yl - methyl) pyridazine en tant qu'antagoniste du recepteur pour le nmda | |
| MA26864A1 (fr) | Antagonistes du facteur de liberation de corticotrophine. | |
| MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
| MA28020A1 (fr) | Phényl-ou pyridylamides servant d'antagonistes de la prostaglandine E2 | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| MA30556B1 (fr) | COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| MA28432B1 (fr) | Antagonistes du recepteur de la chimiokine | |
| MA27582A1 (fr) | Derives benzazepine pour le traitement de troubles neurologiques | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| ATE315022T1 (de) | Prostaglandinanaloga als ep4-rezeptoragonisten | |
| MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
| MA30284B1 (fr) | Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| WO2005051946A3 (fr) | Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique | |
| MA27775A1 (fr) | Composes organiques | |
| MA32151B1 (fr) | Derives de 2-aza-bicyclo[2.2.1]heptane | |
| TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
| MA27569A1 (fr) | Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases | |
| MA31323B1 (fr) | Agents therapeutiques | |
| MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
| MA26952A1 (fr) | Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques. | |
| MA31000B1 (fr) | Derives 2-aza-bicyclo[3.1.0]hexane | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| MA27197A1 (fr) | Sels de tolterodine |